Project Portfolio

Group A Streptococcus Vaccine
Group A Streptococcus Vaccine
Technology Platform: Infectious Disease

PREVENT, in collaboration with Vaxent, Inc. is developing a 30-valent vaccine which will provide coverage for at least 95% of North American and 90% of European GAS infections, as well as significant protection in the rest of the world. Phase I clinical study will be initiated in 2015.

Group A streptococci (GAS) are ubiquitous human pathogens that cause a wide spectrum of clinical syndromes. Acute infections range from uncomplicated pharyngitis, cellulitis, and pyoderma to necrotizing fasciitis (flash-eating disease), sepsis, pneumonia, and streptococcal toxic shock syndrome. The non-suppurative sequelae that may follow GAS infections are acute rheumatic fever, rheumatic heart disease and post-streptococcal glomerulonephritis. Once initiated, these sequelae cannot be blocked with antibiotic treatment, making vaccination a highly desirable approach for PREVENT.
The M proteins have been functionally defined as surface proteins that a) confer resistance to phagocytosis, and b) contain protective (opsonic) epitopes. The best evidence supports the use of multivalent, type-specific, M protein-based vaccines designed to elicit bactericidal antibodies against epidemiologically significant serotypes of group A streptococci.
PREVENT is developing a 30-valent vaccine which will provide coverage for at least 95% of North American and 90% of European GAS infections, as well as significant protection in the rest of the world.
GAS vaccine development is in collaboration with Vaxent Inc. Vaxent which is an early stage vaccine development company located in Memphis, Tennessee, whose lead product in development is a subunit vaccine against group A streptococcus which has been tested in early stage human clinical trials.
http://innovamemphis.com/joomla-overview/62-vaxent
Phase I clinical study initiation in 2015.

  • More Details- Less Details
    Chlamydia Vaccine
    Chlamydia Vaccine
    Technology Platform: Infectious Disease

PREVENT and the British Columbia Centre for Disease Control are collaborating to develop a vaccine targeting Chlamydia trachomatis. The project has utilized immunoproteomics sequence analysis and experimentation to select lead vaccine candidates. Pre-clinical studies will be completed in 2015 to be followed by human clinical trials.

Worldwide Chlamydia trachomatis is responsible for over 92 million sexually transmitted infections and 85 million ocular infections annually. In Canada, C. trachomatis is the most common reportable communicable disease with near 10,000 cases reported annually in British Columbia (BC) alone. One in ten women in N. America has a Chlamydia infection.
Public health programs have targeted C. trachomatis as a major problem because of the ability of the organism to cause long-term sequelae such as infertility, ectopic pregnancy and blindness. In developed countries, public health measures to prevent and control Chlamydia appear to be failing as case rates continue to rise and efforts to control Chlamydia are not feasible using current approaches.
Using an immunoproteomics approach several Chlamydia proteins were identified which have the potential to form the basis of a protective vaccine; further sequence analysis and experimentation has led to the selection of lead vaccine candidates.
Chlamydia vaccine development is in collaboration with the British Columbia Centre for Disease Control (BCCDC). The BCCDC provides provincial and national leadership in public health through surveillance, detection, treatment, prevention and consultation services. The Centre provides both direct diagnostic and treatment services for people with diseases of public health importance and analytical and policy support to all levels of government and health authorities.
www.bccdc.ca
Pre-clinical non-human primate studies will be completed in 2015 prior to any decision to proceed to clinical trials.

  • More Details- Less Details
    Influenza-PAL Vaccine
    Influenza-PAL Vaccine
    Technology Platform: Adjuvant Technology

PREVENT, in collaboration with Folia Biotech, is developing an influenza vaccine that is combined with a novel adjuvant designed to enhance the immune response and broaden serotype coverage. Phase I clinical study initiation for this vaccine is scheduled for April 2014.

This platform combines influenza vaccine with a novel adjuvant to enhance the immune response.
The PAL adjuvant is based on the immunogenic potential of recombinant viral-like particles (rVLDs) derived from a papaya plant virus which, when combined with the appropriate antigen, stimulates both the innate and the adaptive immune systems.
The PAL-Flu vaccine appears to generate a stronger immune response to influenza and to provide broader protection covering flu strains that are not contained in the annual seasonal tri-valent vaccine.
Flu-PAL development is in collaboration with Folia Biotech, which is a Canadian biotechnology company whose core technology is vaccine enhancement through a remarkable new adjuvant derived from the coat protein of the papaya mosaic virus (PapMV).
www.foliabiotech.com
Phase I clinical study initiation in April 2014.

  • More Details- Less Details
    RSV-P3 Vaccine
    RSV-P3 Vaccine
    Technology Platform: Adjuvant Technology

PREVENT in collaboration with the Vaccine and Infectious Disease Organization/International Vaccine Centre (VIDO-InterVac), is developing a vaccine that combines the RSV F-protein immunogen with a novel adjuvant. Phase l clinical study is slated to begin in early 2015.

Apart from the selective use of a passive antibody for high-risk infants, there is currently no approved vaccine against respiratory syncytial virus (RSV). RSV is a leading cause of severe respiratory disease, particularly in infants but also in the elderly.
PREVENT’s product combines the RSV F-protein immunogen with a patented defined novel adjuvant that stimulates a balanced immune response involving both virus neutralizing antibodies and cell-mediated immunity.
RSV-P3 development is in collaboration with the Vaccine and Infectious Disease Organization/International Vaccine Centre (VIDO-InterVac). VIDO is a non-profit research organization within the University of Saskatchewan, and is focused on investigating the pathogenesis of infectious diseases and the development of effective therapeutic and prophylactic methods to control infectious diseases of humans and animals.
www.vido.org
Phase I clinical study initiation in early 2015.

  • More Details- Less Details
    CWD Vaccine
    CWD Vaccine
    Technology Platform: Misfolding Disease

PREVENT, VIDO, and the University of British Columbia (UBC) are collaborating to develop a vaccine for CWD composed of a recombinant chimeric protein fused to an inactivated bacterial toxin. A challenge study in Elk will be initiated in April 2014.

The emergence of prion-based chronic wasting disease (CWD) in Canada threatens both wild and farmed cervids (deer, elk, caribou, moose) populations. It is not unreasonable to expect that uncontrolled disease will eventually spread across species. CWD in cervids may act as a disease reservoir for either direct, or indirect, transmission to traditional livestock, which would have a devastating impact on the livestock industry, and disease in the migrating caribou herds would expand the CWD range across the entire country. Also, wild cervids are a traditional food source in northern populations so spread into northern moose and caribou could place additional economic and cultural stress on these communities. Although CWD is currently thought to be restricted to cervids, and there is no direct evidence of transmission to humans, the potential to infect humans exists. Unlike the recent BSE outbreak, CWD cannot be dealt with by simply controlling feed additives. CWD exists in wild populations that cannot be effectively contained or segregated from livestock; the disease agent can persist in the environment for decades without a host.
This program was initiated following the discovery that the YYR epitope is specifically exposed on misfolded prions and hidden in the normal form and that antibodies to YYR can block prion infectivity.
The vaccine product is a recombinant chimeric protein consisting of several repeats of an epitope exposed on misfolded prions presented as a recombinant C-terminal fusion to an inactivated bacterial toxin which helps amplify the immune response.
CWD vaccine development is in collaboration with VIDO and University of British Columbia (UBC). VIDO is a non-profit research organization at the University of Saskatchewan, and is focused on investigating the pathogenesis of infectious diseases and the development of effective therapeutic and prophylactic methods to control infectious diseases of humans and animals. The University of British Columbia (UBC), established in 1908, is one of Canada’s leading research universities and is consistently ranked among the top 40 in the world.
www.vido.org
www.ubc.ca
A disease challenge study in Elk will be initiated in April 2014.

Continue Reading

PREVENT’S Technology Platforms

Infectious Disease

Vaccines have historically targeted the prevention of infectious diseases. Most current vaccines have been approved for use in infants and young children to protect against childhood infectious diseases. More recent advancements in vaccine technology and research have expanded vaccine utilization into adolescent and adult populations. PREVENT is currently working on three vaccines for infectious diseases, Group A Streptococci, Respiratory Syncytial Virus and Chlamydia for which no vaccines exist.

Adjuvant Technology

Adjuvants are substances sometimes included in vaccines to improve and enhance the immune-stimulating properties of the vaccine. PREVENT is developing two adjuvants, P3 and PAL adjuvants, which are both expected to elicit a stronger and more balanced immune improving effectiveness in immunologically challenged populations including infants and the elderly, extending the range of protection to include more disease variants, and expanding protection to include intracellular pathogens. If successful, these novel adjuvants could be used in a variety of vaccines.

Misfolding Disease

The concept of a therapeutic vaccine originated in the oncology field in the 1980’s. PREVENT is developing a unique platform within the therapeutic and prophylactic vaccine fields with the intent to target immune responses to naturally occurring proteins but specific to regions of the protein that are only exposed when the protein is misfolded and thus causes disease. Misfolded proteins are thought to be responsible for a number of human disease problems including Creutzfeldt-Jacob’s, Alzheimer’s, and ALS. As a demonstration / proof –of-concept strategy for this platform, PREVENT is developing a vaccine for the treatment of chronic wasting disease (CWD).

Continue Reading

Our Current Partners

The PREVENT partnership is led by an extensive body of expertise including a team of over fifty internationally recognized authorities on infectious diseases from:
Our Founding Partners:

VIDO-InterVacVaccine and Infectious Disease Organization (VIDO-InterVac)

(Saskatoon, Saskatchewan): The internationally recognized organization provides for a preclinical research capacity (Containment Level 2 laboratory and animal facilities) for immunogenicity and animal-model disease studies within the PREVENT effort. The International Vaccine Centre (InterVac), is Canada’s largest Level 3 Containment laboratory dedicated to vaccine development, and it has the capacity to test vaccines in large animals challenged with biosafety level 3 pathogens. Dr. Andy Potter is the Chief Executive Officer of VIDO-InterVac.

The Canadian Center for Vaccinology

The Canadian Center for Vaccinology (CCfV) (Halifax, Nova Scotia): A partnership among Dalhousie University, the IWK Health Centre and Capital Health houses a 30,000 square foot vaccine research centre for clinical trials (Phase I-III). Research is undertaken here at both basic and translational science levels. The CCfV focuses on epidemiology, implementation and evaluative policy research. Dr. Scott Halperin is the Executive Director of the CCfV.

The British Columbia Centre for Disease Control

The British Columbia Centre for Disease Control (BCCDC) (Vancouver, British Columbia): The BCCDC undertakes and evaluates discovery research for the PREVENT effort. The BCCDC is a provincial and national leader in public health through surveillance, detection, treatment, and prevention and consultation services. The Centre provides leadership on immunization practices for the province and provides analytical and public support to government and health authorities. Dr. Robert Brunham is the Executive Director of the BCCDC and a professor of Medicine, UBC.

Our Funders:

The Networks of Centres of Excellence of CanadaThe Networks of Centres of Excellence of Canada, a joint initiative of the Natural Sciences and Engineering Research Council, the Social Sciences and Humanities Research Council, the Canadian Institutes of Health Research, Industry Canada and Health Canada.

Our Commercial Partners :

Amorfix

Amorfix: PREVENT, UBC and Amorfix are collaborating to develop a vaccine for amyotrophic lateral sclerosis (ALS, Lou Gehrig disease). Amorfix Life Sciences Ltd is a theranostics company developing therapeutic products and diagnostic devices targeting misfolded protein diseases including BSE, ALS, cancer, and Alzheimer’s Disease.

British Columbia Centre for Disease Control (BCCDC): PREVENT, UBC, and the BCCDC are collaborating to develop a vaccine targeting Chlamydia trachomatis. The BCCDC provides provincial and national leadership in public health through surveillance, detection, treatment, prevention and consultation services. The Centre provides both direct diagnostic and treatment services for people with diseases of public health importance and analytical and policy support to all levels of government and health authorities.

Folia BiotechFolia Biotech: PREVENT and Folia Biotech are collaborating to develop an influenza vaccine combined with a novel adjuvant designed to enhance the immune response. Folia Biotech is a Canadian biotechnology company whose core technology is vaccine enhancement through a remarkable new adjuvant derived from the coat protein of the papaya mosaic virus (PapMV).

VIDO-InterVac: PREVENT and VIDO-InterVac are collaborating to develop a vaccine that combines the respiratory syncytial virus (RSV) F-protein immunogen with a patented defined novel adjuvant. VIDO is a non-profit research organization owned by the University of Saskatchewan, and is focused on investigating the pathogenesis of infectious diseases and the development of effective therapeutic and prophylactic methods to control infectious diseases of humans and animals.

UBC The University of British Columbia (UBC): PREVENT, the Brain Research Centre at UBC, and VIDO are collaborating to develop a vaccine for misfolded prion proteins. The UBC was established in 1908, is one of Canada’s leading research universities and is consistently ranked among the top 40 in the world. The Brain Research Centre, located in Vancouver, Canada, is a unique partnership between Vancouver Coastal Health Research Institute and the Faculty of Medicine at the University of British Columbia. The hospital has combined forces with broad, multi- disciplinary research expertise at the University of British Columbia to advance knowledge of the brain and to explore new discoveries and technologies that have the potential to reduce the suffering and cost associated with disease and injuries of the brain.

Vaxent Inc.Vaxent Inc.: PREVENT and Vaxent are collaborating in the development of a 30-valent vaccine for group A streptococcus (GAS). Vaxent is an early stage vaccine development company located in Memphis, Tennessee, whose lead product in development is a subunit vaccine against group A streptococcus (GAS), earlier versions of which have been tested in early stage human clinical trials with no adverse events.

Continue Reading

Become a Partner

PREVENT targets new vaccines, improved vaccine formulations, and delivery strategies developed at Canadian universities, research institutions, university spin-offs, biotech companies, and other sources. By partnering with PREVENT you gain access to:

  • Risk Mitigation: PREVENT identifies successful vaccine candidates and develops them to a stage where significant commercial value has been added to these technologies and risk has been adequately diminished to encourage subsequent commercialization activities.
  • Expertise: PREVENT works with industry partners to develop vaccine candidates for the marketplace, with the technologies transferred to receptor organizations either in the private or public sector.
  • An Accelerated Market Pathway: PREVENT assists in fast-tracking zoonotic veterinary and human vaccine development for diseases of major public health concern, and navigates a pathway to commercialization that promotes growth, investment, and improved global competitiveness for Canada’s vaccine industry.
  • Resources: PREVENT provides financial and directs technical advancements for post-proof-of-principle vaccine candidates that have at minimum demonstrated efficacy in a relevant animal model, and which also hold promise for managing serious disease issues.
Continue Reading

You Can Increase Your Penis Hardness By Doing These 5 Things.

Do you normally have a weak erection? You will note that you
are not alone. Most men are victims of this circumstance. You will note that
such men cannot fully satisfy a woman in bed. This is because they rarely get a
stiff erection. It is important that you ensure that your penis is hard enough
during sexual intercourse. Penis hardness is normally dependent on the ability
of the heart to pump blood to your penis. If you normally have a weak erection,
you can consider several ideas that can make you increase your penis hardness.
These ideas include:

  • Consider doing exercises.

According to PhalloGauge Medical PDMP Center of Excellence, penis exercises are very important for your body.
This is because they can help you to reduce your weight in the long run. You
will also be able to burn more calories. If you are able to burn fat, you can
be sure that you will unclog your arteries. There are many exercises that you
can consider. Running is a good exercise that can help you to burn excess fat
in your body. This exercise can actually boost blood circulation in your body.
This can help you to get a stiff erection and thereby improve your performance
in bed. You can engage in any physical exercise that suits you. These include
swimming, cycling, playing football and so on.

  • Reduce your stress levels.

We all have ever stress at some point in our lives. However,
you should not allow stress to overwhelm you. You will note that stress can
take a toll on both your libido and erections. If you have anxiety, depression
or even stress, your penis hardness can be negatively affected. This is because
there is a lot of stress hormone cortisol in your blood. It is important that
you reduce this stress as soon as possible. In this case, you can consider
meditation and doing yoga exercises. You can also find a friend whom you can
confide in and open up to him or her. This has proved to be very effective.

  • Change your diet.

Are you fond of taking junk foods? You should change your
diet today. You will note that your diet can affect your penis hardness. You
might not get the stiffness that you want. It is therefore important that you
change your diet and start taking healthy foods. Healthy foods can help you
reduce the chances of getting type 2 diabetes and even obesity. You should
focus more on taking fruits and vegetables. You should always ensure that your
food does not have a lot fat content. This can help increase blood flow in your
penis during sexual intercourse.

  • Reduce the intake of alcohol and cigarettes.

Some people are addicted to alcohol and cigarettes. This can
be detrimental. Your performance in bed might be negatively affected. If you
normally take these substances, you should reduce their intake in order to have
a stronger erection during sexual intercourse.

Consider these ideas today and you will have a hard
erection. This can help you to enjoy sexual intercourse with your partner. You
will also be able to have a high self-esteem. Consider these ideas today and
you will be a happy man.

Continue Reading